The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The group is persevering with Granite, but funds might be hard to come by.